ArticleJournal of molecular medicine (Berlin, Germany)2015
Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer.
Article in Journal of molecular medicine (Berlin, Germany), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Antibody-recruiting molecules based on mimotope fusion peptides and a dimeric antibiotic.bioRxiv : the preprint server for biology · 2026Article
- Global health perspectives on antibacterial drug discovery and the preclinical pipeline.Nature reviews. Microbiology · 2025Review
- Harnessing endogenous anti-glycan antibodies using a novel, bifunctional immunotherapy to treat gram-negative bacterial infections.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Redirecting the host immune response to bacterial infection with antibody-recruiting molecules (ARMs).Current opinion in chemical biology · 2025Review
- Antibiotics re-booted-time to kick back against drug resistance.npj antimicrobials and resistance · 2025Review
- Siderophore-based targeted antibody recruitment for promoting immune responses towards Gram-negative pathogens.RSC chemical biology · 2025Article
- Aptamers: precision tools for diagnosing and treating infectious diseases.Frontiers in cellular and infection microbiology · 2024Review
- Alpha-Gal Bound Aptamer and Vancomycin Synergistically ReduceMicroorganisms · 2023Article
- miR-132-3p regulates antibody-mediated complement-dependent cytotoxicity in colon cancer cells by directly targeting CD55.Clinical and experimental immunology · 2023Article
- Applications in Which Aptamers Are Needed or Wanted in Diagnostics and Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Antibiotic-chemoattractants enhance neutrophil clearance of Staphylococcus aureus.Nature communications · 2021Article
- Induction of Endogenous Antibody Recruitment to the Surface of the PathogenACS infectious diseases · 2021Article
- Synthetic Glycobiology: Parts, Systems, and Applications.ACS synthetic biology · 2020Review
- Binding and Structural Properties of DNA Aptamers with VEGF-A-Mimic Activity.Molecular therapy. Nucleic acids · 2020Article
- AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models.Cancer cell international · 2019Article
- Potential Inherent Stimulation of the Innate Immune System by Nucleic Acid Aptamers and Possible Corrective Approaches.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Synthetic Immunobiotics: A Future Success Story in Small Molecule-Based Immunotherapy?ACS infectious diseases · 2018Article
- Aptamers in the Therapeutics and Diagnostics Pipelines.Theranostics · 2018Review
- A Simple Platform for the Rapid Development of Antimicrobials.Scientific reports · 2017Article
- Synthetic peptides mimicking lipopolysaccharide as a potential vaccine candidates againstIranian journal of microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
unlabelledThe ever-increasing threat of multi-drug resistant bacterial infections has spurred renewed interest in alternative approaches to classical antibiotic therapy. In contrast to other mammals, humans do not express the galactose-α-1,3-galactosyl-β-1,4-N-acetyl-glucosamine (α-Gal) epitope. As a result of exposure of humans to α-Gal in the environment, a large proportion of circulating antibodies are specific for the trisaccharide. In this study, we examine whether these anti-Gal antibodies can be recruited and redirected to exert anti-bacterial activity. We show that a specific DNA aptamer conjugated to an α-Gal epitope at its 5' end, herein termed an alphamer, can bind to group A Streptococcus (GAS) bacteria by recognition of a conserved region of the surface-anchored M protein. The anti-GAS alphamer was shown to recruit anti-Gal antibodies to the streptococcal surface in an α-Gal-specific manner, elicit uptake and killing of the bacteria by human phagocytes, and slow growth of invasive GAS in human whole blood. These studies provide a first in vitro proof of concept that alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response. Further validation of this novel therapeutic approach of applying α-Gal technology in in vivo models of bacterial infection is warranted. KEY MESSAGES: . α-Gal-tagged aptamers lead to GAS opsonization with anti-Gal antibodies. . α-Gal-tagged aptamers confer phagocytosis and killing of GAS cells by human phagocytes. . α-Gal-tagged aptamers reduces replication of GAS in human blood. . α-Gal-tagged aptamers may have the potential to be used as novel passive immunization drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.